Bridgewest Group acquires Pfizer manufacturing facility in Perth

Global investment firm Bridgewest Group has acquired the Perth sterile injectable manufacturing facility of pharmaceutical giant Pfizer with assistance from Thomson Geer.  

The 34,000 sq m facility has over 400 employees and produces a wide range of sterile injectable drug products for distribution to over 90 countries. 

The acquisition included the property on which the manufacturing facility is conducted as well as a range of drug products.  The plant will operate as a Contract Development and Manufacturing Organization (CDMO) moving forward and will continue to produce drug products for Pfizer under a manufacturing master services agreement. 

Thomson Geer advised on all aspects of the transaction for Bridgewest, including all property related matters, manufacturing and supply agreements, Foreign Investment Review Board approval, trade marks, GST, environmental and employment related issues. 

The Thomson Geer team was jointly led by Partner Mark Feetham and Special Counsel Delene Blumberg, who congratulated Bridgewest on its latest acquisition as it expands its investments in the pharmaceutical sector. 

"We're pleased to have supported Bridgewest on all aspects of the transaction with expertise from across the firm, enabling a smooth and seamless process," they said. 

Mark and Delene were assisted by Partners Mark Borrello, Julius Skinner, George Hodson and Jonathon Corlett, Special Counsel Nadine Frost and Helen Jin, Senior Associate Diane Sargeant, and Lawyers Christian Teng and Roy Leigh.

Thomson Geer also advised Bridgewest Group on its acquisition of Pfizer's Adelaide facility in 2021, now known as BioCina.

‍

‍